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http://www.hqlo.com/content/12/1/1RESEARCH Open AccessValidation of the International Prostate Symptom
Score in Chinese males and females with lower
urinary tract symptoms
Edmond PH Choi*, Cindy LK Lam and Weng-Yee ChinAbstract
Objectives: To evaluate the translation of the IPSS (Hong Kong Chinese version 1) and to assess the applicability,
validity, reliability and sensitivity of the instrument in both males and females with LUTS in Chinese population.
Methods: The translation of the IPSS (Hong Kong Chinese version 1) was reviewed through back translation.
Modifications were made, resulting in the development of The IPSS (Hong Kong Chinese version 2). The content
validity was assessed by contend validity index. 233 subjects with LUTS were recruited in Hong Kong primary care
settings for pilot psychometric testing. The construct validity was assessed by corrected item-total correlation and
Pearson’s correlation test against ICIQ-UI SF, IIQ-7 and SF-12 v2. The reliability was assessed by the internal
consistency (Cronbach’s Alpha coefficient) and test –retest reliability (Intraclass correlation coefficient). The Sensitivity
was determined by performing known group comparisons by independent T-test.
Results: The content validity index for all items could reach 1. Corrected item-total correlation scores were ≥0.4 for
four symptom questions (feeling of incomplete bladder emptying, intermittency, weak stream and straining). Overall,
the total symptom score moderately correlated with ICIQ-UI SF. The quality of life score moderately correlated with
the IIQ-7 but weakly correlated with SF-12 v2. Overall, the reliability of the IPSS (Hong Kong Chinese version 2) was
acceptable (Cronbach’s Alpha coefficient = 0.71, ICC of the symptom questions =0.8, ICC of the quality of life
question =0.7). The symptoms questions and quality of life questions of the IPSS (Hong Kong Chinese versions
2) were sensitive in detecting differences between groups.
Conclusions: The IPSS (Hong Kong Chinese version 2) is a valid, reliable and sensitive measure to assess Chinese
females and males with lower urinary tract symptoms. The IPSS quality of life question is more sensitive than the
generic quality of life measure to differentiate subgroups.
Keywords: Questionnaires, Psychometric, Lower urinary tract symptoms, Quality of life, Urinary bladder diseasesBackground
Lower urinary tract symptoms (LUTS) are common,
particular among the elderly. LUTS have adverse impact
on health- related quality of life (HRQOL). Most of the
treatments like surgery, medication and behavioral the-
rapy aim to reduce the symptom severity and alleviate
the negative impact on HRQOL. In both clinical practice
and research, the symptom severity and the negative im-
pact of LUTS should be accurately assessed and properly* Correspondence: h0714919@hku.hk
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stated.recorded. Patient report outcome measures usually in
the form of questionnaire provide a method for the stan-
dardized collection of data from patients. The American
Urological Association (AUA) symptom index is a 7-
item questionnaire originally developed and validated by
the AUA [1]. It asks about the severity of LUTS namely,
incomplete bladder emptying, frequency of urination,
intermittency, urgency, weak urine stream, straining and
nocturia. Each of the questions is rated from 0 (not at all)
to 5 (almost always). The total symptom score is the sum
of questions 1–7. According to the total symptom score,
the severity of LUTS can be graded as mild (0–7), mode-
rate (8–19) and severe (20–35). The AUA symptom indexd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Organization with the addition of one item on quality of
life and renamed the International Prostate Symptom
Score (IPSS) for assessing males with LUTS. The answers
to the quality of life question range from 0 (delighted) to 6
(terrible). The IPSS has been translated into several lan-
guages and is widely used in clinical practice and research,
however, only the French, Spanish, Malay, Japanese and
Arabic versions have been reported to be valid and reliable
for assessing males with LUTS [2-6]. Furthermore, the
IPSS was originally developed for assessing LUTS in
males. Several studies have also used the IPSS to assess fe-
males with LUTS [7,8]. It has been found to be a valid and
reliable patient reported outcome measure for females
with LUTS in Japan [9].
Translating well-established instruments into differ-
ent languages, and testing its validity to prove that the
attributes being measured in various settings are the
same is needed to enable cross-cultural comparisons of
findings. It is needed to ensure the adapted instrument
is conceptually equivalent to the original version and
relevant and culturally acceptable to the target popula-
tion. This is known as cross-cultural adaptation. The
IPSS was translated into Chinese by the Hong Kong
Urological Association (HKUA) in 1995 [10] and has
been used in clinical practice and research for asses-
sing Chinese male patients with LUTS. To date how-
ever, the translation and psychometric performance of
the IPSS (Hong Kong Chinese version 1) has never
been examined. The objectives of this study were to
evaluate the translation of the IPSS (Hong Kong Chinese
version 1), to refine the translation if required, and to
assess the applicability, validity, reliability and sensitivity
of the instrument in both Chinese males and females
with LUTS.
Methods and subjects
Evaluation on the translation of the IPSS (Hong Kong
Chinese version 1)
The IPSS (Hong Kong Chinese version 1) was back
translated into English by a professional translator who
was blind to the original IPSS. The back translation was
reviewed against the original English IPSS by two bilin-
gual authors (EPHC and CLKL) and a third author
(WYC) who is a native English speaker. According to
the International Society For Pharmacoeconomics and
Outcomes Research (ISPOR), some constructs like med-
ical symptoms require more literal translation whilst
subjective constructs like health- related quality of life
need to be more conceptually equivalent [11]. Discre-
pancies between the back translation and original English
version were identified. Items were revised by the authors
resulting in the development of the IPSS Hong Kong
Chinese version 2 (IPSS HKv2).Content validity
Cognitive debriefing interviews on the IPSS HKv2 were
subsequently conducted on ten Chinese (Cantonese)
speaking patients with LUTS to assess the clarity, re-
levance and interpretation of each question and response
option by the first author (EPHC). Subjects for the cog-
nitive debriefing interviews were recruited by convenience
sampling, balanced for age and sex, from a nurse-led con-
tinence clinic. The following questions were asked: (1)
whether the subjects could understand the questions and
response options, (2) to interpret what the questions
and response options meant by subjects’ own wording,
(3) whether the questions and response options were
relevant to lower urinary tract symptoms. The answers
of the interviews were recorded verbatim. Both bilin-
gual authors (EPHC and CLKL) reviewed the results of
the cognitive debriefing interviews. The IPSS HKv2 was
finalized and pilot tested on males and females with
urinary symptoms.
Pilot psychometric testing of the IPSS
Subjects for pilot testing of the IPSS HKv2 were re-
cruited from 2 different settings to include patients
with a cross spectrum of disease severity. One group,
patients with LUTS attending nurse-led continence
clinics, were recruited by consecutive sampling. The
other group, primary care patients with LUTS attend-
ing general outpatient clinics were identified by waiting
room screening. The screening instrument used was
adapted from the International Consultation on Incon-
tinence Questionnaire-Urinary Incontinence Short Form
(ICIQ-UI SF) using scores ≥ 3 to identify eligible subjects.
The English translation of the adapted ICIQ-UI SF was
shown in Additional file 1. Subjects from both settings
were excluded if they were aged <18 years, could not
understand Cantonese, refused to participate, or were
too ill to give consent.
Eligible patients were approached by a field worker
who explained the aims, procedures and nature of the
study. Subjects who consented were asked to provide
their contact details and were contacted within two
weeks of recruitment by trained research assistants
who administered the study instruments by telephone
interview. Patients recruited from general outpatient
clinic waiting rooms were contacted again two-weeks
after their baseline interview to collect data for test-
retest reliability.
A sample size of 200 subjects (100 subjects in contin-
ence clinics and 100 subjects in general outpatient
clinics) was planned based on the recommendation for
pilot psychometric testing [12]. This sample with 100
subjects in each group (continence clinics and general
outpatient clinics) was able to detect a statistically sig-
nificant difference between groups by independent T-test
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Cohen’s effect size of 0.4.
Patients gave written informed consent fo the use of
their data. The study was approved by the institutional
review boards: HKWC (UW 12-558), HKEC (HKEC-
2010-095), KWC (KW/EX/10-149(34-16)) and KEC (KC/
KE-10-0209/ER-3).
Study instruments
In addition to the IPSS HKv2 the following instruments
were administered to subjects to evaluate convergent
validity.
Incontinence impact questionnaire – short form (IIQ-7)
The IIQ-7, which consists of 7 questions, was originally
used to evaluate the impact of urinary incontinence on
health -related quality of life. The psychometric properties
were tested in females in Hong Kong [13]. The term “uri-
nary leakage” was modified to “urinary problems” in the
present study in order to extend the scope of application
of the measure. The total score is the sum of questions
1–7. The higher the total score of the IIQ-7, the more
the negative impact on health- related quality of life.
Consultation on incontinence questionnaire-urinary
incontinence short form (ICIQ-UI SF)
The ICIQ-UI SF consists of four questions to assess the
frequency (question 1) and amount of urinary leakage
(question 2), the impact of urinary leakage on quality of
life (question 3) and the perceived causes of urinary leak-
age (question 4) [14]. The term “urinary leakage” was
modified to “urinary problems” in frequency and quality
of life questions to extend the scope of application of
the measure. The total score is the sum of question 1–3.
Higher scores indicate higher symptom severity and
greater impact on health- related quality of life. The
fourth question is an unscored question about the per-
ceived caused of urinary incontinence.
Short form 12, version 2 (SF-12v2)
SF-12 v2 is a generic health-related quality of life measure,
which covers eight domains namely physical functioning,
role limitation due to physical problems, bodily pain, gen-
eral health, vitality, social functioning, role limitation due
to emotional problems and mental health. SF-12 v2 can
be summarized into physical and mental component sum-
mary (PCS and MCS) scores with higher scores indicating
better quality of life. It has been validated for use in Hong
Kong primary care patients [15].
Global rating of change scale
The single item scale asks subjects to rate the change in
his/her health since their baseline interview and was ad-
ministered to subjects who participated in the two-weekfollow-up telephone interview for assessing test-retest
reliability. Only subjects who rated no change in their
health over the 2-week period were included for evalu-
ation of test-retest reliability.
Data analysis
The content validity index (CVI) on clarity and rele-
vance was assessed by examining the proportion of di-
chotomous responses “yes” or “no”. Items with CVI ≥0.8
were considered to have good content validity [16].
Descriptive statistics, including mean, standard devi-
ation, and percentage of floor and ceiling of scores were
calculated. 15% was used as the threshold for a signifi-
cant floor or ceiling effect [17].
The internal construct validity of the IPSS HKv2 was
assessed by examining the corrected item- total scale
correlation using corrected item-total scale correlation
scores ≥0.4 to identify adequate correlation [18]. The con-
vergent validity of the IPSS was assessed using Pearson’s
correlation test against ICIQ-UI SF, IIQ-7 and SF-12 v2. It
was hypothesized that IPSS HKv2 total symptom score
would have a moderate correlation (correlation coefficient
between 0.4 and 0.6) with ICIQ-UI SF as both measure
clinical symptoms. It was hypothesized that IPSS HKv2
quality of life score would have a stronger correlation with
IIQ-7 than SF-12 v2 because both IPSS HKv2 quality of
life question and IIQ-7 are condition-specific measures.
The internal consistency of the IPSS was assessed by
Cronbach’s alpha using cut-off scores ≥ 0.7 to indicate
adequate internal consistency [19]. Test-retest reliability
was assessed by examining the intra-class correlation co-
efficient (ICC). ICC ≥ 0.7 was used to indicate good re-
producibility [17].
Sensitivity of the IPSS HKv2 was determined by per-
forming known group comparisons of the mean total
symptom and quality of life scores by independent T-
test. It was hypothesized that patients attending nurse-
led continence clinics would have higher symptom
scores and poorer health-related quality of life because
their condition had already been identified by a doctor
and required further management. Conversely, it was hy-
pothesized that patients recruited from general out-
patient clinics would have comparatively lower IPSS
HKv2 symptom and quality of life scores as these pa-
tients were identified by screening and had not sought
help for their symptoms.
All psychometric properties, except sensitivity, were
analyzed by gender groups and overall. All statistical
analyses were performed using SPSS 20.0.
Results
Translation
Back-translation of the IPSS (Hong Kong Chinese version
1) revealed that all questions, aside from the item on
Table 1 Characteristics of subjects of pilot
psychometric testing
Characteristics CCs GOPCs Overall
n = 100 n = 133 n = 233
1. Mean age (SD) 61.5 (11.5) 64.4 (11.2) 63.2 (11.5)
2. Age group (years, %)
18-65 62.0 54.9 57.9
Above 65 38.0 45.1 42.1
3. Gender (%)
Male 52.0 41.4 45.9
Female 48.0 58.6 54.1
4. Marital status (%)
Married 76.0 72.9 74.2
Single 5.0 4.5 4.7
Widower 14.0 15.8 15.0
Divorced 5.0 6.8 6.0
5. Employment status (%)#
Working 42.0 27.8 33.9
Not working 58.0 72.2 66.1
6. Household income (%)
<HKD20.000 63.0 61.7 62.2
HKD20,000 or the above 29.0 21.8 24.9
Missing 8.0 16.5 12.9
7. Smoking status (%)
Never 71.0 78.2 75.1
Ex-smoker 23.0 13.5 17.6
Current smoker 2.0 2.3 2.1
Refused to answer 4.0 6.0 5.2
8. Drinking status (%)
Never 44.0 49.6 47.2
Ex-drinker 15.0 12.0 13.3
Current drinker 38.0 30.8 33.9
Refused to answer 3.0 7.5 5.6
CCs: continence clinics.
GOPCs: general outpatient clinics.
n = number of subject.
#Significant difference between patients in CCs and GOPCs by chi-square
test (P < 0.05).
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to the original English version The IPSS (Hong Kong
Chinese version 1) uses a dichotomous leading question
“Have you often…” which asks for a “Yes” or “No” re-
sponse, whereas, the original English IPSS uses “How often
have you…” which asks about the frequency of the urinary
symptom. The quality of life item was also problematic in
the IPSS (Hong Kong Chinese version 1) as the translation
did not incorporate the meaning “the rest of your life with
your urinary condition”. Two of the response options for
the symptom-related questions, and all five response op-
tions of the quality of life question were not equivalent to
the original English version. Additional file 2 shows all
non-equivalent questions and response options.
Through panel review, all nonequivalent questions and
response options were modified to enhance their transla-
tional equivalence to the original English version. The
panel also further refined one of the response options
for the quality of life question (“unhappy”) even though
back-translation was equivalent to original English ver-
sion. This was done to enhance clarity and make it easier
for respondents to compare the response options.
Content validity
Ten subjects were recruited for cognitive debriefing in-
terviews: five males, five females; age range 23–70 years
(mean 54.2 years). All subjects were able to correctly in-
terpret each item and response options. The CVI on
clarity and relevance of all items reached 1.0.
Applicability and response rates
Two hundred and third three subjects were recruited for
pilot psychometric testing of the IPSS HKv2. Five sub-
jects could not complete the questionnaire. 98% of the
data was analyzable. Baseline characteristics of study
subjects are shown in Table 1. The mean time taken to
complete the IPSS HKv2 was 2.40 minutes. The subject
recruitment flowchart is shown in Figure 1.
Psychometric performance
Table 2 shows the distribution of the responses for each
item of the IPSS HKv2 by gender. For the total symptom
score, 1.8% of subjects (2.4% female; 1.0% male) had the
lowest possible score whilst no ceiling effect was ob-
served. For the quality of life score, 4.7% of subjects
(4.8% female; 4.7% male) had lowest possible score while
4.3% of subjects (3.2% female; 5.7% male) had highest
possible score.
Table 2 shows the results of corrected item-total cor-
relation testing for the items on urinary symptoms. Cor-
rected item-total correlation scores were ≥0.4 for four
symptoms, but did not reach the standard of 0.4 for
items on frequency, urgency and nocturia.Table 2 shows the internal consistency and test-retest
reliability of the IPSS HKv2. Cronbach’s alpha coeffi-
cient was 0.7 for the seven symptom-related items in
males while 0.68 in females. Test-retest reliability was
assessed in 77 patients whose global rating of change
scale showed no change in their health between the
baseline and 2-week interviews. Overall the ICC of the
IPSS HKv2 total symptom and quality of life scores
exceeded 0.7, and exceeded 0.8 in males. The ICC of
the IPSS HKv2 quality of life question was only 0.58 in
females.
Figure 1 Subject recruitment flowchart.
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of total symptoms and quality of life scores against the
ICIQ-UI SF, IIQ-7, SF-12v2 PCS and MCS scores. The
IPSS HKv2 total symptom score had a moderate correl-
ation with ICIQ-UI SF (Pearson’s correlation coefficient of
0.44 in females and 0.50 in males). The IPSS HKv2 quality
of life score had a moderate correlation with IIQ-7 butweak correlations with SF-12v2 PCS and MCS. In males,
there was no significant correlation between the IPSS
HKv2 quality of life score and SF-12 PCS.
Table 4 shows the sensitivity of the IPSS HKv2 in de-
tecting differences between subjects recruited from con-
tinence care clinics and those recruited from general
outpatient clinic waiting rooms. As expected, statistically
Table 2 Score distribution, corrected item-total correlation and reliability of the IPSS (HK v2) by gender
Female Male Overall
n Mean (SD) Corrected item-
total correlation
n Mean (SD) Corrected item-
total correlation
n Mean (SD) Corrected item-
total correlation
1. Incomplete
emptying
126 1.02 (1.22) 0.52 107 1.90 (1.61) 0.58 233 1.42 (1.47) 0.58
2. Frequency 126 2.01 (1.61) 0.37 106 2.37 (1.68) 0.36 232 2.17 (1.65) 0.38
3. Intermittency 126 0.79 (1.34) 0.54 107 1.41 (1.82) 0.56 233 1.07 (1.61) 0.57
4. Urgency 126 1.28 (1.60) 0.35 107 1.39 (1.67) 0.27 233 1.33 (1.63) 0.30
5. Weak stream 125 0.66 (1.22) 0.56 107 1.39 (1.56) 0.54 232 1.00 (1.43) 0.57
6. Straining 126 0.46 (1.03) 0.40 107 0.82 (1.39) 0.41 233 0.63 (1.22) 0.42
7. Nocturia 125 3.38 (1.89) 0.19 105 3.75 (1.65) 0.18 230 3.55 (1.79) 0.20
Total symptom score 124 9.50 (5.88) 104 13.03 (6.81) 228 11.11 (6.55)
8. Quality of life 126 3.20 (1.89) 106 3.24 (1.80) 232 3.22 (1.85)
Female Male Overall
n Floor Ceiling n Floor Ceiling n Floor Ceiling
Total symptom score 124 2.40% 0.00% 104 1.00% 0.00% 228 1.80% 0.00%
8. Quality of life score 126 4.80% 3.20% 106 4.70% 5.70% 232 4.70% 4.30%
Female Male Overall
Cronbach’s alpha 0.68 0.70 0.71
Female Male Overall
Intraclass correlation n n n
Total symptom score 40 0.75 37 0.81 77 0.80
Quality of life score 41 0.58 38 0.84 79 0.70
CCs: continence clinics.
GOPCs: general outpatient clinics.
n = number of subject with valid answer.
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groups for IPSS HKv2 total symptom score (effect size
0.34) and quality of life scores (effect size 0.64). Simi-
larly, significant differences were detected between the
groups for ICIQ-UI SF (effect size 0.38) and IIQ-7 (effect
size 0.30). There was no significant difference between
groups for SF-12v2 PCS and MCS.
Comments
Back translation of the IPSS (Hong Kong Chinese version
1) identified several questions and response options whichTable 3 Correlations of the IPSS (HK v2) with ICIQ-UI SF, IIQ-7
ICIQ -UI S
Female The IPSS total symptom score 0.44**
The IPSS quality of life score
Male The IPSS total symptom score 0.50**
The IPSS quality of life score
Overall The IPSS total symptom score 0.47**
The IPSS quality of life score
**Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).were not equivalent to the original English instrument.
First, “have you” instead of “how often” is used for every
question in the Hong Kong version 1. When respondents
first read the question, they might only focus on whether
they have the particular symptom and may not expect to
consider the frequency of the symptom, causing discrep-
ancies in how they might respond. Second, the meaning of
“the rest of your life” is missed in the quality of life ques-
tion in the Hong Kong Chinese version 1. Its purpose in
the original instrument is to ask respondents to consider
how they would feel if their urinary problems lasted until, SF 12 v2
Pearson’s correlations
F IIQ-7 SF 12 PCS SF 12 MCS
0.50** −0.22* −0.18*
0.40** −0.10 −0.28**
0.46** −0.17* −0.21**
Table 4 Sensitivity in detecting differences between subjects from CC and GOPC
CC GOPC
Scale Mean (SD) Mean (SD) P-value ES
The IPSS total symptom score 12.33 (6.36) 10.16 (6.56) 0.013 0.34
The IPSS quality of life score 3.86 (1.67) 2.74 (1.83) <0.001 0.64
The ICIQ-UI SF 8.48 (3.99) 6.94 (4.01) 0.004 0.38
The IIQ-7 3.77 (4.13) 2.59 (3.75) <0.024 0.30
The SF-12 PCS 46.46 (9.14) 46.08 (9.58) 0.764 0.04
The SF-12 MCS 52.59 (10.88) 53.44 (10.26) 0.545 0.08
CCs: continence clinics.
GOPCs: general outpatient clinics.
ES: effect size.
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the respondent might only consider the current or short-
term impact of their urinary problem. Such translational
discrepancies threatens the validity of data [20], and can
affect its cross-cultural interpretability. This is the first
study to support the content validity of the IPSS for both
male and female patients LUTS. Both males and females
could understand and correctly interpret the question
items and response options. It confirmed that the ques-
tions of the IPSS are not gender specific.
In item-total correlation testing, the symptom-related
items on frequency, urgency and nocturia had poor cor-
relation in females and males. These three symptoms are
predominantly storage symptoms and may suggest that
these items are measuring a related but slightly different
domain than the other items of the IPSS HKv2.
The IPSS HKv2 total symptom score moderately corre-
lated with the ICIQ-UI SF which confirms that the con-
structs of both measures are related but not equivalent.
The IPSS quality of life question had a moderate correl-
ation with IIQ-7 but weak correlation with SF-12v2 sug-
gesting that there is a difference in the construct of the
IPSS quality of life question and that of the SF-12v2. Since
SF-12v2 is a generic health-related quality of life measure,
the domains of such measures might not be specific and
sensitive enough to capture the impact of LUTS on
health-related quality of life. Generic measures contain ir-
relevant domains and may miss specific concerns held by
the respondents [21]. On the contrary, the IIQ-7 is a
condition-specific measure, so the domains of IIQ-7
should be more relevant to those with LUTS. Our results
support the added value of condition-specific measures.
Interestingly, the IPSS HKv2 quality of life score only
correlated with SF-12v2 MCS in men whilst there is a
stronger correlation between IPSS HKv2 quality of life
score and SF-12v2 PCS in women. This shows that the
impact of LUTS on quality of life is different for males
and females. The present study showed that LUTS ap-
pears to have a greater impact on mental health than
physical health in men, whereas the opposite occurs inwomen. These findings are consistent with the validation
study of the Spanish IPSS [3]. Males with LUTS are wor-
ried and embarrassed [22], and have concerns about sex-
ual competence and prostate cancer [23]. Men with
LUTS might therefore have more mental health burden.
Conversely, in women, overactive symptoms such as ur-
gency and frequency appear to have a more negative im-
pact on physical functioning than mental health [24,25].
The IPSS HKv2 was found to be a reliable patient re-
ported outcome measure in both males and females.
Overall, the internal consistency (Cronbach’s alpha >0.7)
of the IPSS HKv2 appears to be comparable to the ori-
ginal English instrument [1]. The Cronbach’s alpha was
slightly below standard in females, which is still accept-
able. The 2-week test-retest reliability in patients with
stable health condition was acceptable and comparable
to other versions of the IPSS [1,3,26]. The intra-class
correlation coefficients of IPSS HKv2 total symptom and
quality of life scores were above 0.7 with the exception
of the quality of life question in female subjects (ICC =
0.578) implying that this single-item measure is com-
paratively unreliable in women [12]. Clinicians and re-
searchers should interpret the responses to this item
with caution and should not rely on the IPSS single-item
quality of life question to monitor patients longitudinally
or for evaluation of treatment effect.
The finding of higher IPSS HKv2 total symptom sever-
ity and poorer health-related quality of life in patients
recruited from continence clinics than general out-
patient clinics shows that the instrument is sensitive to
differentiate patients with varying disease severity. It
should be noted that the IPSS quality of life question
had a larger effect size than all the other measures sug-
gesting that this single-item measure may have high sen-
sitivity to differentiate subgroups. Our findings also
suggest that an individual’s perceived impact on health-
related quality of life might be a determinant for patients
to seek medical advice. From our data, it appears that
the SF-12v2 may not be sensitive enough to detect dif-
ferences between patients in continence clinics and
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and not sufficiently sensitive to detect subgroup differences
[27,28]. Our findings indicate that condition-specific
measures outperform generic measures for detecting
differences between subgroups of patients with urinary
symptoms.
Limitations
The subjects were recruited in the government-funded pri-
mary care setting by convenient sampling. Patients in pri-
vate primary care setting or in secondary care were not
included in the pilot psychometric testing. The responsive-
ness of the instrument (its ability to detect change over
time) still needs to be assessed. Subjects in this study were
mainly Cantonese speakers and the content validity and
psychometric performance of the instrument should be
further tested with Mandarin speakers or Chinese speakers
of different nationalities.
Conclusions
The IPSS Hong Kong Chinese version 2 (IPSS HKv2) is
both conceptually and linguistically equivalent to the
original English IPSS and the present study has shown
its applicability, content validity, construct validity, reli-
ability and sensitivity. The IPSS quality of life question is
sensitive than generic health- related quality of life measure
to differentiate subgroups. We hope the measure can be
applied for Chinese in the worldwide diaspora.
Additional files
Additional file 1: Screening questionnaire (adapted ICIQ-UI SF).
Additional file 2: Nonequivalent questions and response options of
the IPSS (Hong Kong version 2).
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